



## Syndicated Thought Leader Insight

---

### **Thought Leader Insight & Analysis Report** **Rheumatology Q2 2010**

<b>Therapeutic Class:</b>	Autoimmune Disorders
<b>Focus Area:</b>	Rheumatoid Arthritis (major focus), Lupus, Vasculitis, Osteoarthritis (minor focus)
<b>Specialty/Location:</b>	Rheumatologists / North America, Europe
<b>Number of Interviews:</b>	6
<b>Number of Pages:</b>	123
<b>Publication Date:</b>	April 2010
<b>Principal Authors:</b>	Kim Grant Tricia L. Hanlon Jeffrey D. Berk, Ph.D., MBA
<b>Product Code:</b>	MAIRQ210-29
<b>Pricing:</b>	\$7,000
<b>Order Info:</b>	www.medpredict.com or call (513) 271-1924

**Abstract:** This report is based on six primary interviews conducted with American and European rheumatology thought leaders in March/Early April 2010. Our in-depth discussions include key development activities in the rheumatology pipeline, perspectives on unmet needs and how different mechanisms are likely to address these, and updates on most promising compounds in development. The Panel also addresses potential winners and losers under increasing healthcare cost pressures in the U.S. and Europe. Specific topics discussed in this report include:

- RA pain,
- New approaches to the treatment of osteoarthritis signs & symptoms:
  - FGF18
  - BMP-7
  - NGF,
- How are diagnostics/biomarkers being developed in concert with anti-rheumatics?
- B-cell approaches,
- CCR,
- CTLA4,
- GMCSF,
- JAK,
- IL-6,
- IL-17,
- Interferon, and
- Syk.

***This report provides essential strategic insight for key stakeholders in the rheumatology market at a significant value versus customized primary research.***

**Drugs/Mechanisms Discussed in this Report:**

<b>Company</b>	<b>Drug</b>	<b>Brand</b>
Abbott	adalimumab	Humira
Alder / BMS	ALD-518	
Amgen / Wyeth / Pfizer	etanercept	Enbrel
Array	ARRY-438162	
AstraZeneca	GM-CSF-CCL2 fusokine CCR5 P2X7	
Bristol-Myers Squibb	abatacept	Orencia (iv, sc)
Centocor / Schering-Plough (Merck)	infliximab golimumab	Remicade Simponi
ChemoCentryx / GSK	CCX-354	
Genentech / Roche	rituximab ocrelizumab PRO-131921 rontalizumab (rhuMAb IFN alpha)	Rituxan / MabThera
Genentech / Roche / Chugai	tocilizumab	Actemra / RoActemra
GlaxoSmithKline / Human Genome Sciences	belimumab	Benlysta
Incyte / Novartis (for cancer only)	INCB-18424	
Incyte / Lilly (for non-cancer only)	INCB-28050	
Lilly	LY2439821	
Merck (Schering-Plough; DNAX)	IL-17	
Merck Serono	AS902330 atacicept	
Millennium / Takeda	MLN-3897	
Novartis	AIN-457	
Pfizer	tasocitinib; CP-690550 WYE-152038 CP-481715 tanezumab etanercept	Enbrel
Rigel/AstraZeneca	fostamatinib (R788)	
Stryker	BMP-7	OP-1
Trubion / Pfizer	TRU-015	
UCB	certolizumab	Cimzia

## Table of Contents

Executive Summary.....	4
Top Ten Report Highlights.....	6
Key Findings.....	16
General Comments.....	16
Target Indications.....	16
Diagnostics.....	16
Pain.....	19
Rheumatoid Arthritis.....	19
Osteoarthritis.....	21
One-Payer Systems.....	22
3 <sup>rd</sup> -World Markets.....	24
Therapeutics (Alphabetical by Mechanism).....	25
B-cell.....	25
MabThera / Rituxan (rituximab; Genentech / Biogen-Idec).....	25
ocrelizumab (Genentech).....	29
Benlysta; belimumab (HGS/GSK), atacicept (Merck Serono).....	31
TRU-015 (Pfizer / Trubion).....	32
BMP-7.....	32
OP-1; Stryker.....	32
CCR (chemokine receptor antagonists).....	33
CP-481715 (Pfizer); Perspectives on CCR1 Receptor Occupancy.....	35
GM-CSF-CCL2 fusokine, CCR5 (separate programs from AstraZeneca).....	37
Boehringer Ingelheim.....	37
Bristol-Myers Squibb.....	38
CCX-354 (ChemoCentryx / GlaxoSmithKline).....	38
MLN-3897 (Millennium).....	38
CTLA4.....	40
Orencia; abatacept (BMS).....	40
FGF18.....	45
AS902330 (Merck Serono).....	45
IL-6.....	46
Actemra (tocilizumab; Roche / Chugai).....	46
ALD-518 (Alder / BMS).....	49
IL-17.....	50
LY2439821 (Lilly).....	51
AIN-457 (Novartis).....	52
(DNAX; Merck).....	52
Interferon.....	53

rontalizumab (Genentech).....	53
JAK.....	54
Tasocitinib CP-690550 (Pfizer).....	54
INCB28050 (Lilly / Incyte).....	61
WYE-152038 (Wyeth / Pfizer).....	62
MEK.....	62
ARRY-438162 (Array).....	62
NGF Antibody.....	63
tanezumab (Pfizer / Rinat).....	63
NSAID.....	63
Pennsaid; diclofenac lotion (Dimethaid).....	63
P2X7.....	64
AstraZeneca.....	64
Syk.....	64
fostamatinib (Rigel / AstraZeneca).....	64
TNF / PDE4.....	67
Enbrel (etanercept; Amgen / Pfizer).....	68
Thought Leader Interviews.....	69
Interview BJE02385.....	69
Interview BJE02417.....	78
Interview BJE02418.....	88
Interview BJE02419.....	97
Interview BJE02420.....	105
Interview BJE02422.....	114